Paul Hamberg

4.2k citations

121 papers · 2.2k · h-index 27

Impact in

Cancer Research top 5%
- Cancer Genomics and Diagnostics
- Cancer, Lipids, and Metabolism
Pulmonary and Respiratory Medicine top 2%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment

Papers in

Pulmonary and Respiratory Medicine 71
- Prostate Cancer Treatment and Research 42
- Renal cell carcinoma treatment 16
Oncology 49
- Cancer Treatment and Pharmacology 16
- Colorectal Cancer Treatments and Studies 9
- Cancer Cells and Metastasis 6

Co-authors: Stefan Sleijfer (33 shared papers)Jaap Verweij (13 shared papers)Ronald de Wit (33 shared papers)Ron H.J. Mathijssen (31 shared papers)John W.M. Martens (22 shared papers)Jaco Kraan (19 shared papers)Anieta M. Sieuwerts (13 shared papers)Martijn P. Lolkema (25 shared papers)
Journals: Journal of Clinical Oncology (19 papers)European Journal of Cancer (12 papers)Annals of Oncology (7 papers)Molecular Oncology (4 papers)International Journal of Cancer (4 papers)
Partner nations: Netherlands United States Belgium

In The Last Decade

Paul Hamberg

113 papers receiving 2.1k citations

Peers

Countries citing papers authored by Paul Hamberg

Since Specialization

Citations

This map shows the geographic impact of Paul Hamberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Hamberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Hamberg more than expected).

Fields of papers citing papers by Paul Hamberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Hamberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Hamberg. The network helps show where Paul Hamberg may publish in the future.

Co-authors

The 25 scholars most cited alongside Paul Hamberg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Paul Hamberg Line = papers co-authored together Paul Hamberg links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 121 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells European Urology ·Wendy Onstenk, Anieta M. Sieuwerts, Jaco Kraan, Mai N. Van, Annemieke J.M. Nieuweboer, Ron H.J. Mathijssen, Paul Hamberg, Hielke J. Meulenbeld, Bram De Laere, Luc Dirix, Robert J. van Soest, Martijn P. Lolkema, John W.M. Martens, Wytske M. van Weerden, Guido Jenster, John A. Foekens, Ronald de Wit, Stefan Sleijfer	2015	201
2	(Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor The Oncologist ·Paul Hamberg, Jaap Verweij, Stefan Sleijfer	2010	130
3	Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment Cancer ·Sushil K. Badrising, Vincent van der Noort, Inge M. van Oort, H. Pieter van den Berg, Maartje Los, Paul Hamberg, Jules L.L.M. Coenen, Alfons J.M. van den Eertwegh, Igle J. de Jong, Emile D. Kerver, Harm van Tinteren, Andries M. Bergman	2013	111
4	Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors Clinical Cancer Research ·José Baselga, Andrés Cervantes, Erika Martinelli, Isabel Chirivella, Klaas Hoekman, Herbert I. Hurwitz, Duncan I. Jodrell, Paul Hamberg, (unknown), Paul Elvin, Alan Swaisland, Renee Iacona, Josep Tabernero	2010	96
5	Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells European Journal of Cancer ·Lisanne Mout, Lisanne F. van Dessel, Jaco Kraan, Anouk C. de Jong, Rui P. Neves, Sigrun Erkens‐Schulze, Corine M. Beaufort, Anieta M. Sieuwerts, Job van Riet, Thomas Woo, Ronald de Wit, Stefan Sleijfer, Paul Hamberg, Yorick Sandberg, Peter A.W. te Boekhorst, Harmen J.G. van de Werken, John W.M. Martens, Nikolas H. Stoecklein, Wytske M. van Weerden, Martijn P. Lolkema	2021	60
6	Local NSAID Gel (Eltenac) in the Treatment of Osteoarthritis of the Knee: A double blind study comparing eltenac with oral diclofenac and placebo gel Scandinavian Journal of Rheumatology ·Jerker Sandelin, Arsi Harilainen, Hans Crone, Paul Hamberg, B. Forsskåhl, Gösta Tamelander	1997	60
7	Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression As First-Line Chemotherapy in Patients with HER2+ Metastatic Breast Cancer: HERTAX Trial Clinical Breast Cancer ·Paul Hamberg, Monique M.E.M. Bos, Hans J. Braun, Jacqueline M. Stouthard, Gert A. van Deijk, Frans Erdkamp, Iris N. van der Stelt-Frissen, M. Bontenbal, Geert-Jan Creemers, Johanneke E.A. Portielje, Hans Pruijt, O. J. L. Loosveld, Willem M. Smit, E.W. Muller, Paul Schmitz, Caroline Seynaeve, Jan G.M. Klijn	2011	51
8	Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients Molecular Oncology ·Nick Beije, Anieta M. Sieuwerts, Jaco Kraan, Ngoc M. Van, Wendy Onstenk, Silvia Rita Vitale, Michelle van der Vlugt‐Daane, Luc Dirix, Anja Brouwer, Paul Hamberg, Felix E. de Jongh, Agnes Jager, Caroline Seynaeve, Maurice P.H.M. Jansen, John A. Foekens, John W.M. Martens, Stefan Sleijfer	2017	51
9	Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat Clinical Pharmacokinetics ·Mathilde Van Veggel, Elsbeth M. Westerman, Paul Hamberg	2017	50
10	The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer European Journal of Cancer ·Robert J. van Soest, Annemieke J.M. Nieuweboer, Ellen S. de Morrée, Dana Chiţu, Andries M. Bergman, S.H. Goey, Monique M.E.M. Bos, Nelly van der Meer, Paul Hamberg, Ronald de Wit, Ron H.J. Mathijssen	2015	49
11	Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients Annals of Oncology ·Bianca Mostert, Anieta M. Sieuwerts, Jaco Kraan, Joan Bolt‐de Vries, Petra van der Spoel, Anne van Galen, Dieter Peeters, Luc Dirix, Caroline Seynaeve, Agnes Jager, Felix E. de Jongh, Paul Hamberg, Jacqueline M. Stouthard, Diederik F.S. Kehrer, Maxime P. Look, Marcel Smid, J.W. Gratama, John A. Foekens, John W.M. Martens, Stefan Sleijfer	2014	45
12	Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor Neoplasia ·Nick Beije, Wendy Onstenk, Jaco Kraan, Anieta M. Sieuwerts, Paul Hamberg, Luc Dirix, Anja Brouwer, Felix E. de Jongh, Agnes Jager, Caroline Seynaeve, Ngoc M. Van, John A. Foekens, John W.M. Martens, Stefan Sleijfer	2016	43
13	Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor Cancer Chemotherapy and Pharmacology ·Paul Hamberg, Margaret M. Woo, Lin‐Chi Chen, Jaap Verweij, Maria Grazia Porro, Lily Zhao, Wenkui Li, D. van der Biessen, Sunil Sharma, Thomas Hengelage, Maja J.A. de Jonge	2011	42
14	Phase I study of AZD0530, an oral potent inhibitor of Src kinase: First demonstration of inhibition of Src activity in human cancers Journal of Clinical Oncology ·Josep Tabernero, Andrés Cervantes, Klaas Hoekman, Herbert I. Hurwitz, Duncan I. Jodrell, Paul Hamberg, Melissa K. Stuart, T. P. Green, Renee Iacona, José Baselga	2007	39
15	CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate‐resistant prostate cancer previously treated with docetaxel International Journal of Cancer ·Michel D. Wissing, Jules L.L.M. Coenen, Pieter van den Berg, Hans M. Westgeest, Alfons J.M. van den Eertwegh, Inge M. van Oort, Monique M.E.M. Bos, Andries M. Bergman, Paul Hamberg, Albert J. ten Tije, Maartje Los, Martijn P. Lolkema, Ronald de Wit, Hans Gelderblom	2014	38
16	Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer Clinical Cancer Research ·Sofie H. Tolmeijer, Emmy Boerrigter, Takayuki Sumiyoshi, Edmond M. Kwan, Sarah W.S. Ng, Matti Annala, Gráinne Donnellan, Cameron Herberts, Guillemette E. Benoist, Paul Hamberg, Diederik M. Somford, Inge M. van Oort, Jack A. Schalken, Niven Mehra, Nielka P. van Erp, Alexander W. Wyatt	2023	32
17	Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study Clinical Chemistry ·Guillemette E. Benoist, Inge M. van Oort, Emmy Boerrigter, Gerald W. Verhaegh, Onno van Hooij, Levi Groen, Frank Smit, Pieter de Mol, Paul Hamberg, Vincent O. Dezentjé, Niven Mehra, Winald R. Gerritsen, Diederik M. Somford, Nielka P. H. van Erp, Jack A. Schalken	2020	32
18	Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors Investigational New Drugs ·Maja J.A. de Jonge, Paul Hamberg, Jaap Verweij, S. Savage, A. Benjamin Suttle, Jeffrey P. Hodge, Thangam Arumugham, Lini Pandite, Herbert I. Hurwitz	2012	31
19	Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients Breast Cancer Research and Treatment ·Lisette Binkhorst, Jacqueline S. L. Kloth, Annelieke S. de Wit, Peter de Bruijn, Mei H. Lam, Inês Chaves, Herman Burger, Robbert J. van Alphen, Paul Hamberg, Ron H. N. van Schaik, Agnes Jager, Birgit C. P. Koch, Erik A.C. Wiemer, Teun van Gelder, Gijsbertus T. J. van der Horst, Ron H.J. Mathijssen	2015	31
20	The Effect of Using Pazopanib With Food vs. Fasted on Pharmacokinetics, Patient Safety, and Preference (DIET Study) Clinical Pharmacology & Therapeutics ·Floor J.E. Lubberman, Hans Gelderblom, Paul Hamberg, Walter L. Vervenne, Sasja F. Mulder, Frank G. A. Jansman, Angela Colbers, Winette T.A. van der Graaf, David M. Burger, Saskia Luelmo, Dirk Jan A. R. Moes, Carla M.L. van Herpen, Nielka P. van Erp	2019	30

About Paul Hamberg

Paul Hamberg is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 121 papers that have together received 2.2k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (42 papers), Renal cell carcinoma treatment (16 papers), Cancer Treatment and Pharmacology (16 papers), Cancer Genomics and Diagnostics (15 papers), Colorectal Cancer Treatments and Studies (9 papers), Radiopharmaceutical Chemistry and Applications (9 papers), Cancer Cells and Metastasis (6 papers) and Multiple Myeloma Research and Treatments (6 papers). The work is most often cited by research in Cancer Research (494 citations), Pulmonary and Respiratory Medicine (926 citations), Oncology (766 citations), Hematology (130 citations) and Radiology, Nuclear Medicine and Imaging (199 citations). Paul Hamberg has collaborated with scholars based in Netherlands, United States and Belgium. Frequent co-authors include Stefan Sleijfer, Jaap Verweij, Ronald de Wit, Ron H.J. Mathijssen, John W.M. Martens, Jaco Kraan, Anieta M. Sieuwerts, Martijn P. Lolkema, Wendy Onstenk and Inge M. van Oort. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Annals of Oncology, Molecular Oncology and International Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Paul Hamberg

Impact in

Papers in i

In The Last Decade

Paul Hamberg

Peers

Countries citing papers authored by Paul Hamberg

Fields of papers citing papers by Paul Hamberg

All Works

About Paul Hamberg

Explore authors with similar magnitude of impact

Papers in